Navigation Links
YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
Date:12/6/2010

Forty-eight (80%) had palpable splenomegaly greater than 10 cm. A number of the patients had discontinued treatment with other JAK inhibitors (INCB018424, n=11; TG101348, n=3) or pomalidomide (n=13). The median time to follow up since study start is currently 4.9 months, ranging from 0.9-12.5 months.

Efficacy Results: - The Overall Response Rate (anemia, spleen) to date, as per the International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria, is 62%. - Anemia Response: Of 42 subjects who were evaluable for anemia response (baseline Hgb less than 10 g/dL or red cell transfusion- dependent), 21 subjects (50%) had achieved Clinical Improvement (CI) as per the IWG-MRT criteria. A 57% response rate was observed in transfusion dependent patients. For the 150 mg/day dosing group, the anemia response rate was 41% (43% for transfusion dependent patients). For the 300 mg/day dosing group, the anemia response rate was 58% (69% for transfusion dependent patients). Responses were observed in five of nine (55%) patients who had discontinued treatment with other JAK inhibitors (INCB018424, TG101348) and 5 of 12 (42%) who had discontinued pomalidomide. - Spleen Size Reduction: Twenty-five (47%) of the 53 evaluable subjects who had splenomegaly at baseline achieved a minimum 50% decrease in palpable spleen size, thus qualifying them for CI per IWG-MRT criteria. For the 150 mg/day dosing group, 53% qualified for CI. For the 300 mg/day dosing group, 46% qualified for CI. - Constitutional Symptoms: CYT387 controlled constitutional symptoms in a significant percentage of patients (night sweats: 88%, bone pain: 80%, pruritus: 92%, fever: 100%).

Safety Results:

In the dose escalation portion of the study, at the highest dose level (400 mg/day), two of six subjects experienced dose limiting toxicity (DLT) (one each of reversible asymptomatic Grade 3 hyperlipasemia and Grade 3 headache); consequently, the maximum tolerated
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
2. Ardea Biosciences to Present at Two Upcoming Investor Conferences
3. YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
4. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
5. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
6. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
7. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
8. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
9. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
10. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
11. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled ... 2pm EST (11am PST), “Natural Language Processing: Converting Raw ... technology can turn raw, heterogeneous data into actionable knowledge ... online webinar will last approximately one hour. , Synopsis: ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest ... research medicinal plants and therapeutic derivatives thereof has ... professionals, and researchers about the challenges of adulterated ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society for ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... PfuTurbo and Taq DNA Polymerases ,,,, pfuturbo ... PCR amplification , , Holly Hogrefe ... In this update, we compare the PCR performances ... DNA polymerase. ,PCR product yields were higher ...
... mutagenesis in less than one day , ... 28-base insertion was introduced into a plasmid vector ... created three unique restriction enzyme digestion sites. Plasmid ... transformed clones were digested with,all 3 restriction enzymes, ...
... Studying Signal Transduction,Pathways ,,,,, Obtaining the best ... ,in vivo reporting systems , Tim Sanchez ... Zheng ,Stratagene , Stratagenes PathDetect ... are used to study,activation of specific signaling pathways ...
Cached Biology Technology:PCR Performance Comparisons Between pfuturbo and Taq DNA,Polymerases 2PCR Performance Comparisons Between pfuturbo and Taq DNA,Polymerases 3PCR Performance Comparisons Between pfuturbo and Taq DNA,Polymerases 4Efficiently Insert Unique Restriction Sites into Plasmid Vectors 2Efficiently Insert Unique Restriction Sites into Plasmid Vectors 3Optimizing Transfection Conditions for Studying Signal Transduction Pathways 2Optimizing Transfection Conditions for Studying Signal Transduction Pathways 3Optimizing Transfection Conditions for Studying Signal Transduction Pathways 4Optimizing Transfection Conditions for Studying Signal Transduction Pathways 5Optimizing Transfection Conditions for Studying Signal Transduction Pathways 6Optimizing Transfection Conditions for Studying Signal Transduction Pathways 7
(Date:7/9/2014)... co-authored by a University of Guelph scientist that ... shows long-term exposure to a neonicotinoid pesticide hampers ... research by Nigel Raine, a professor in Guelph,s ... Imperial College London was published July 9 in ... . , The study shows how long-term pesticide ...
(Date:7/9/2014)... fever but often can be defeated with antibiotics and ... beat. Now, scientists have built a new weapon against such ... the journal ACS Applied Materials & Interfaces , their ... of them than medicine alone. , David Leong, Jianping Xie ... wait, undetectable in the human body or in places that ...
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
Breaking Biology News(10 mins):Bee foraging chronically impaired by pesticide exposure: Study 2First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... Adoptive cell transfer (ACT) therapy is used to treat patients ... of the patient's cancer cells, and some of their immune ... of the cancer cells that stimulate the T cells to ... get expanded and re-infused into the patient to mount an ...
... pandemic influenza, a new study reports for the first time ... from poultry to humans. The research appears in the ... available online. , Crossing the species barrier is an important ... potential. Previous studies have focused on the ability of highly ...
... many scientists thought, genetically modified (GM) corn has not ... , After analyzing tens of thousands of seeds from ... Mexico and the United States found no evidence of ... the researchers, said Allison Snow, a professor of evolution, ...
Cached Biology News:First Whole Genome Map of Genetic Variability in Parkinson’s Disease 2Genetically modified maize not found in southern Mexico 2
... ,Yeast extract, 5 ,Sodium chloride, 10 ... citrate, 0.5 ,IPTG, 0.03 ,-Gal ... chromogenic substrate for -galactosidase. The enzymatic ... a black insoluble precipitate. Lac+ colonies ...
... Polyclonal Antibody Epitope: aa 16-25 of ... Recommended Storage: Store vial at -20 ... use. For extended storage aliquot contents and freeze at -20 ... Family: Other Sub-Family: ...
S-100 alpha/beta chain (8B10)...
... Acetate: CoA ligase (AMP forming), Acetate ... on protein content. Physical form: ... sucrose and reduced glutathione Preparation ... mol of S-acetyl coenzyme A from acetate, ...
Biology Products: